Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Monthly Romosozumab Formulations in Postmenopausal Osteoporosis
2013-000434-35Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of romosozumab in osteoporosis (2 arms), sponsored by Amgen. Primary endpoint: Percent change from baseline in DXA BMD at the lumbar spine. Started Nov 2013; status: completed.
02
Drugs
romosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2013-000434-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000434-35.